2. UroToday Home
  3. Conference Highlights
  4. IBCN 2020

IBCN 2020: The Role of Blue Light Cystoscopy in Detecting Invasive Bladder Tumors: Data from Multi-institutional Registry

(UroToday.com) Dr. Hamed Ahmadi, Society of Urologic Oncology (SUO) Fellow at the University of Southern California, Los Angeles, California, USA presented “The Role of Blue Light Cystoscopy in Detecting Invasive Bladder Tumors: Data from Multi-institutional Registry.”  While Blue Light cystoscopy (BLC) has a defined role in non-muscle-invasive bladder cancer (NMIBC), with increase detection and decreased recurrence rates, its use for invasive tumors is less well defined. 

Dr. Ahmadi et al. investigated BLC in detecting invasive tumors, defined as ≥pT1 lesions, in a prospective, multi-institutional database.  In their series of 47 patients, 11% of all invasive lesions were white light (-) and blue light (+).  Notably, in 82% of patients who underwent radical cystectomy, the high-risk features on trans urethral resection of bladder tumor (TURBT)  leading to definitive surgical management were found only on BLC.  These investigators provide a rationale for use of BLC to increase the detection of high-risk lesions along the spectrum of NMIBC and muscle-invasive bladder cancer (MIBC).

IBCN_2020_Ahmadi_1.png


Presented by: Hamed Ahmadi, MD, SUO Fellow at the University of Southern California, Los Angeles, California, USA

Written by: Dr. Patrick Hensley, Urologic Oncology Fellow at MD Anderson Cancer Center, Twitter: @pjhensley11, with Ashish Kamat, MD, MBBS, President of The International Bladder Cancer Network (IBCN), The International Bladder Cancer Group (IBCG), and Professor of the Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, Twitter: @UroDocAsh, at the International Bladder Cancer Network (IBCN) Annual Meeting, #IBCN2020, October 17, 2020.